Thrombin and FXa plasma concentration levels in patients with atrial fibrillation on long term warfarin therapy
MSH Lim, L Anchah, WN Tiong, SS Hwang, TK Ong, KH Sim, AYY Fong
03 December 2014
April 2014, 22:5
1. Lombardi R, Chantarangkul V, Cattaneo M, Tripodi A. Measurement of warfarin in plasma by high performance liquid chromatography (HPLC) and its correlation with the international normalized ratio. Thromb Res. 2003;111:281–4.
2. Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proceedings. 2001;14:305–6.
3. McMillin GA, Vazquez SR, Pendleton RC. Current challenges in personalizing warfarin therapy. Expert review of clinical pharmacology. 2011;4:349–62.
4. Hammwohner M, Goette A. Will warfarin soon be passe? New approaches to stroke prevention in atrial fibrillation. Journal of cardiovascular pharmacology. 2008;52:18–27.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine. 2009;361:1139–51.
6. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human molecular genetics. 2005;14:1745–51.
7. Scibona P, Redal MA, Garfi LG, Arbelbide J, Argibay PF, Belloso WH. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants. Genetics and molecular research : GMR. 2012;11:70–6.
8. Buzoianu AD, Trifa AP, Muresanu DF, Crisan S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G A polymorphisms in a population from South-Eastern Europe. Journal of cellular and molecular medicine. 2012;16:2919–24.
9. Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, et al. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. Journal of clinical pharmacy and therapeutics. 2012;37:232–6.
10. Edwards F, Arkell P, Fong AY, Roberts LM, Gendy D, Wong CS, et al. Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia. J Thromb Thrombolysis. 2013.
11. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15:213–6.
12. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S–88S.
13. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.
14. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239–45.
15. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine. 2011;365:883–91.
16. Costa GL, Lamego RM, Colosimo EA, Valacio RA, Moreira Mda C. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther. 2012;34:1511–20.
17. Watala C, Golanski J, Kardas P. Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. Thromb J. 2003;1:7.
18. Costa IM, Serralheiro AI, Rodrigues M, Alves G, Falcao AC. Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy. Biomed Pharmacother. 2010;64:130–2.
19. Lind SE, Callas PW, Golden EA, Joyner KA, Jr., Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 1997;8:48–53.
20. Hoppensteadt DA, Kahn S, Fareed J. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs. Clinical chemistry. 1997;43:1786–8.
21. Gulati G, Hevelow M, George M, Behling E, Siegel J. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med. 2011;135:490–4.
22. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol. 2006;132:604–7.
23. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis. 2008;25:61–6.
24. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert review of cardiovascular therapy. 2008;6:57–70.
25. Cosmi B, Palareti G, Moia M, Carpenedo M, Pengo V, Biasiolo A, et al. Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. Thromb Res. 2000;100:279–86.
26. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–9.
27. Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. Best Pract Res Clin Haematol. 2013;26:115–29.
28. Cushman M, Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology. 1996;16:1163–9.
29. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fi brillation: Virchow’s triad revisited. Lancet. 2009;373:155–66.
30. Klement P, Rak J. Emerging anticoagulants: mechanism of action and future potential. Vnitrni lekarstvi. 2006;52 Suppl 1:119–22.
31. Rang HP DM, Ritter JM, Moore PK. Pharmacology. 5th ed. London2003.
32. Walker CP, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. British Journal of Anaesthesia. 2002;88:848–63.
33. Butkowski RJ, Elion J, Downing MR, Mann KG. Primary structure of human prethrombin 2 and alpha-thrombin. J Biol Chem. 1977;252:4942–57.
34. Mitamura H. A unique warfarin therapy in Japan. Circ J. 2011;75:2048–9.
35. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors. Circ J. 2011;75:2087–94.
36. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91:472–7.
37. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8:2182–91.
38. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390–6.
39. Paul B, Oxley A, Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol. 1987;40:94–8.
40. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246–53.
41. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891–6.
42. Turpie A. Warfarin replacements: Mechanisms underlying emerging agents. Can J Cardiol. 2008;24:56C–60C.
43. Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103–14.
44. Cannon CP, Stecker EC. New options for stroke prevention in atrial fibrillation. Am J Manag Care. 2010;16:S291–7.
45. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523–32.